Therapy News and Research

RSS

Advanced age associated with poorer bladder cancer-specific survival in radical cystectomy patients

Traditional wisdom taught in urological residency has been that healthy octogenarians with bladder cancer may be offered radical cystectomy without a significantly increased incidence of postoperative complications.

18 Apr 2007

Vitamin D: sunshine, diet and supplements - cancer prevention and therapy

Vitamin D deficiency is common and cancer risk is higher among those individuals with low vitamin D levels, according to an analysis of research which will be presented at a symposium by Donald L.

17 Apr 2007

Brain tumor vaccine shows promise

A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.

17 Apr 2007

Thrombogenics announces agreement with Millipore for commercialization of stem cell technology

ThromboGenics NV has announced that it has completed a global license agreement with Millipore Corporation under which ThromboGenics will exclusively license its technology for production of the proprietary stem cell culture medium marketed by Millipore as RESGRO(x).

17 Apr 2007

Selenium as therapy for prostate cancer

Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.

17 Apr 2007

Study identifies trends in cerebral aneurysm treatment

Cerebrovascular disease is a leading cause of serious long-term disability, affecting as many as 700,000 people every year.

17 Apr 2007

Predicting cancer risk in the long term

Every day, people make assumptions, educated and not, about their risk for developing cancer.

17 Apr 2007

Natalizumab (Tysabri) reduces vision loss in MS patients

According to a study that appears in the April 17 issue of Neurology, researchers at the University of Pennsylvania School of Medicine have found that natalizumab (TYSABRI), a drug that slows disability and reduces relapse rates in patients with multiple sclerosis (MS), also reduces vision loss in patients with relapsing MS.

17 Apr 2007

Connection between cancer development and Darwinian evolution explored

Cancer is a natural consequence of human evolution. Our genes have not developed to give us long and happy lives.

17 Apr 2007

Most-at-risk nursing home residents to be tested for superbugs

A Johns Hopkins study of adult patients admitted to The Johns Hopkins Hospital showed that patients who resided in nursing homes or other kinds of long-term care facilities at any time within the last six months were far more likely than other adult patients to carry or be infected with a drug-resistant superbug.

17 Apr 2007

AccessPharmacy helps meet demands of pharmacy education

In five years, nearly 300,000 practicing pharmacists will be needed nationwide to serve an aging population, a 30 percent increase compared with 2002, according to the U.S. Department of Labor.

17 Apr 2007

Intrathecal Baclofen for spasticity-related pain in amyotrophic lateral sclerosis

An estimated 5,600 people in the United States are diagnosed every year with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, and as many as 30,000 Americans have the disease at any given time.

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Deep brain stimulation helps improve memory in patients with psychiatric illness

Researchers from the Cleveland Clinic will present results of a study today that shows deep brain stimulation (DBS) is associated with improvements on formal memory tests in patients with severe psychiatric illness.

17 Apr 2007

Mellowing with age helps you live longer!

While mellowing with age has often been thought to have positive effects, a Purdue University researcher has shown that doing so could also help you live longer.

17 Apr 2007

Cetuximab improves survival and slows progression of colorectal cancer

Research presented at the 2007 Annual Meeting of the American Association for Cancer Research confirmed that there is now an effective treatment option for colorectal cancer patients for whom all other treatment options have been exhausted, cetuximab.

17 Apr 2007